Rucaparib
Maintenance Rucaparib After Chemo Extends PFS in Some Metastatic Urothelial Cancers
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib following platinum-based ...
APRIL 18, 2022
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 20, 2020
FDA Grants New Indication for Rubraca
The FDA granted a new indication for Rubraca for the maintenance treatment of recurrent ovarian, fallopian tube or ...
APRIL 6, 2018
Load more